

# Caring for Carcinoid Foundation

E-Update: Number 5, 2005

## Research results

The Caring for Carcinoid Foundation is delighted to announce the first results of its genetically-based carcinoid research. Dr. Daniel Chung at Massachusetts General Hospital has completed the first phase of his proteomic analysis. Six months after receiving his Caring for Carcinoid Foundation [research grant](#), Dr. Chung has already made significant progress.

Proteomic analysis has never been performed for carcinoid cancer. It is a powerful way to analyze the genetic causes of carcinoid and will lead to new, targeted therapies. According to Dr. Chung:

"The overall goal of this project is to determine whether there are unique protein expression patterns in gastrointestinal (GI) neuroendocrine tumors that can provide novel insights into disease pathogenesis. Through this approach, we hope to identify specific therapeutic targets that have been previously unrecognized."

[Read Dr. Chung's research results and see one of his proteomic photographs](#)

## Dr. Chung's proteomic research

Dr. Chung is a member of our [Board of Scientific Advisors](#) and a highly distinguished scientist:

- Assistant Professor of Medicine, Harvard Medical School
- Director of the Gastrointestinal Cancer Genetics Clinic, Massachusetts General Hospital
- MD, Harvard Medical School
- BA, Harvard University, *summa cum laude* in Biochemistry

Dr. Chung is blazing a new path in carcinoid research that will help lead to a cure. Dr. Chung's work is based on proteomics, one of the most advanced fields in science. The National Cancer Institute document, "Proteomics and Cancer", explains how proteomics is revolutionizing our understanding of cancer. [Continued here](#)

We are honored to support Dr. Chung and his pioneering efforts to apply cutting-edge proteomics to carcinoid. His talent and commitment will help us cure carcinoid.

## All carcinoid is genetic

The Caring for Carcinoid Foundation supports only genetically-based carcinoid research because it is the only path to discover a cure. Therefore, our efforts to discover a cure will benefit **ALL** carcinoid patients.

As a reminder, **ALL** carcinoid is genetic. Unfortunately, people frequently confuse "genetic" with "inherited". "Genetic" means that a genetic mutation occurs in your body that disrupts the replication of normal cells and gives rise to tumor cells. Scientists estimate that 90-95% of all cancer is caused by genetic mutations that occur during a person's lifetime--not by mutations passed from parents to children. Genetic mutation during a

person's lifetime is called "acquired," as opposed to "hereditary." Novartis Oncology, the manufacturer of Sandostatin, explains in "Causes of Cancer" that all cancer is genetic and is nearly always based on acquired genetic mutations, not hereditary. [Continued here](#)

The American Society of Clinical Oncology also provides additional information in "The Genetics of Cancer". [Continued here](#)

## **Unite to "Cure Carcinoid Now"!**

To discover a cure for carcinoid, it will take a team effort by the entire carcinoid community. Our funded scientists are already making tremendous progress toward unlocking the genetic causes of carcinoid and developing targeted, curative therapies. We need to expand and accelerate this research effort by awarding new research grants in 2006. Please support the "[Cure Carcinoid Now](#)" campaign.

[Donate now!](#)

[Caring for Carcinoid Foundation](#)